T. Rowe Price Associates
RNAC icon

T. Rowe Price Associates’s Cartesian Therapeutics RNAC Stock Holding History

T. Rowe Price Associates’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+10,758
New +$79.7K ﹤0.01% 3131
2024
Q1 		– Sell
-901
Closed -$19K – 2973
2023
Q4 		$19K Buy
901
+112
+14% +$3.34K ﹤0.01% 2876
2023
Q3 		$26K Sell
789
-727
-48% -$24.3K ﹤0.01% 2839
2023
Q2 		$51K Buy
1,516
+789
+109% +$28.2K ﹤0.01% 2801
2023
Q1 		$31K Hold
727
– – ﹤0.01% 2829
2022
Q4 		$25K Hold
727
– – ﹤0.01% 2868
2022
Q3 		$36K Hold
727
– – ﹤0.01% 2870
2022
Q2 		$29K Buy
727
+149
+26% +$4.42K ﹤0.01% 2911
2022
Q1 		$21K Buy
578
+113
+24% +$7.07K ﹤0.01% 2956
2021
Q4 		$45K Sell
465
-47
-9% -$5.06K ﹤0.01% 2929
2021
Q3 		$64K Buy
512
+25
+5% +$3.02K ﹤0.01% 2893
2021
Q2 		$61K Buy
+487
New +$58K ﹤0.01% 2888
2020
Q1 		– Sell
-2,713
Closed -$194K – 2552
2019
Q4 		$194K Sell
2,713
-762
-22% -$36.8K ﹤0.01% 2411
2019
Q3 		$182K Sell
3,475
-2,721
-44% -$145K ﹤0.01% 2398
2019
Q2 		$333K Sell
6,196
-27
-0.4% -$1.84K ﹤0.01% 2272
2019
Q1 		$442K Sell
6,223
-1,773
-22% -$112K ﹤0.01% 2164
2018
Q4 		$638K Buy
7,996
+30
+0.4% +$6.85K ﹤0.01% 1986
2018
Q3 		$3.72M Buy
7,966
+11
+0.1% +$4.42K ﹤0.01% 1490
2018
Q2 		$3.16M Buy
7,955
+7
+0.1% +$2.48K ﹤0.01% 1498
2018
Q1 		$2.43M Buy
7,948
+1
+0% +$285 ﹤0.01% 1530
2017
Q4 		$2.34M Buy
7,947
+3
+0% +$1.31K ﹤0.01% 1546
2017
Q3 		$4.35M Hold
7,944
– – ﹤0.01% 1458
2017
Q2 		$4.73M Buy
7,944
+2,864
+56% +$1.27M ﹤0.01% 1420
2017
Q1 		$2.18M Sell
5,080
-3,200
-39% -$1.35M ﹤0.01% 1558
2016
Q4 		$4.26M Buy
+8,280
New +$4.84M ﹤0.01% 1438

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's RNAC Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 10,758 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #3131 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in RNAC as recently as Q4 2023.

T. Rowe Price Associates first reported a position in RNAC in Q4 2016 and has held it in 25 quarters since. The position peaked at $4.73M in Q2 2017. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • T. Rowe Price Associates held 10,758 shares of Cartesian Therapeutics worth $113K as of Q2 2026.
  • Cartesian Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3131 holding.
  • T. Rowe Price Associates first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 25 quarters since.
  • T. Rowe Price Associates's Cartesian Therapeutics position peaked at $4.73M in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.